Some people carry Alzheimer’s damage yet stay sharp, and scientists think they know why

 

Will your competent? doctor and hospital get further research going so you can be like Bernadette the nun?(The link has disappeared but any competent doctor will know exactly what Bernadette represents!)

Some people carry Alzheimer’s damage yet stay sharp, and scientists think they know why

Some people carry the biological hallmarks of Alzheimer’s disease in their brains yet stay mentally sharp, and scientists believe they are closing in on why. According to ScienceDaily, a study from the Netherlands Institute for Neuroscience suggests the answer may lie in how a rare group of brain cells responds to damage.

The existence of people who resist Alzheimer’s despite having its physical signature has long puzzled researchers and hinted at a hidden protective mechanism. Understanding that resilience could be as valuable as understanding the disease itself, because it points toward what keeps a brain functioning even under attack.

Resilience despite the damage

Researchers have long puzzled over individuals whose autopsies reveal the plaques and tangles associated with Alzheimer’s but who showed little or no cognitive decline in life. The new work points to immature neurons — a small population of cells — and how they react when the brain is under assault, as a possible source of that resilience.

 Related video: Study identifies protein that could help protect memory as we age (WKYC-TV Cleveland) 

These immature neurons, capable of adapting and maturing, may help the brain compensate for damage rather than succumb to it. If their response is what preserves memory in resilient individuals, then bolstering that same response could, in principle, help others withstand the disease’s physical toll — a very different goal from simply removing the toxic proteins.

Why this angle is promising

Much Alzheimer’s research has focused on removing the toxic proteins that accumulate in the disease. Studying resilience flips the question: instead of asking only what causes decline, it asks what protects against it. If the brain has natural defenses that keep some people sharp, understanding those defenses could point toward ways to strengthen them in others. Years of drug development aimed at clearing plaques have produced only modest results, which has pushed the field to look for complementary strategies. Learning how some brains stay sharp despite the damage offers one such path: rather than fighting the pathology directly, treatments might aim to enhance the brain’s own capacity to cope with it.

A different route to treatment

Identifying the cells and mechanisms behind cognitive resilience could eventually inform therapies aimed at preserving memory rather than only clearing plaque. That approach is early and far from a treatment, but it reflects a broader shift in the field toward understanding why some brains withstand Alzheimer’s pathology — a question whose answer could matter as much as understanding the damage itself. Turning insights about immature neurons into a therapy would require far more research, and animal or laboratory findings do not always translate to patients. But the resilience angle broadens the search for solutions beyond the plaque-clearing strategies that have dominated the field, and it holds out the possibility of protecting cognition even when the disease’s physical hallmarks are present. This article was researched with the help of AI, with human editors creating the final content.

The aging brain that doesn’t fail: how neural resilience masks neurodegeneration

Have your competent? doctor provide you EXACT PROTOCOLS for cognitive reserve and resilience. A competent? doctor would have distributed the recovery protocol that Pedro Bach-y-Rita  used to recover fully back in 1958 with only a partial brain! But you don't have a competent doctor, do you? Hasn't done anything so you can be like Bernadette the nun? Lost the link but your doctor should know about her.

NO? So, willing to DO NOTHING, LIKE USUAL!

cognitive reserve (51 posts to November 2014)
cognitive resilience (18 posts to September 2014)

cognitive rehabilitation (34 posts to December 2015)

 The aging brain that doesn’t fail: how neuralresilience masks neurodegeneration

Andrew Eisen , Heather D. Durham & Erik Pioro To cite this article: Andrew Eisen , Heather D. Durham & Erik Pioro (27 Jul 2026): The aging brain that doesn’t fail: how neural resilience masks neurodegeneration, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, DOI: 10.1080/21678421.2026.2705693 To link to this article: https://doi.org/10.1080/21678421.2026.2705693

ANDREW EISEN 1 2 1 , HEATHER D. DURHAM 2 & ERIK PIORO 1 Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada, and Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada 

Abstract 

 Neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease are usually framed as consequences of aging-related pathogenic processes, including impaired proteostasis with protein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. Yet, most individuals, even into advanced age, do not develop clinically significant neurodegenerative disease. This discrepancy suggests that the nervous system possesses robust and redundant protective mechanisms that maintain neural integrity despite cumulative molecular and cellular stress. In this perspective, we propose that neurodegenerative diseases arise not simply from the presence of pathogenic processes, but when integrated resilience systems fail to maintain homeostasis or when reserve mechanisms no longer compensate for accumulated pathology. We have synthesized a threshold-based model of disease emergence based on evidence across proteostasis, mitochondrial function, neuroimmune regulation, glial biology, network-level compensation, and barrier integrity, while integrating genetic, environmental, developmental, and stochastic modifiers. We distinguish biological resilience, which actively limits or repairs pathology, from reserve, which permits function despite pathology. We further propose that clinical disease emerges only when age-related cumulative stress exceeds the combined capacity of resilience and reserve. Reframing neurodegeneration as a failure of preservation systems offers new directions for pre vention and therapeutic development. 

Keywords: Aging, neurodegeneration, senescence, resilience 

Some brains survive Alzheimer’s damage. Scientists think they know how

Will your competent? doctor and hospital get further research going so you can be like Bernadette the nun?

NO? So, willing to DO NOTHING, LIKE USUAL!

 

ASK YOUR COMPETENT? DOCTOR EXACTLY HOW MUCH OF THEIR DOING NOTHING WILL PREVENT DEMENTIA!

Some brains survive Alzheimer’s damage. Scientists think they know how

Scientists may have uncovered a crucial clue to one of the biggest mysteries in Alzheimer’s disease: why some people develop dementia while others do not.

A new study published in Nature Medicine analyzed donated brain tissue from older adults with and without cognitive decline, as well as cognitively healthy centenarians.

Their findings suggest that the way certain immune cells in the brain respond to Alzheimer’s-related damage may play a key role in determining whether the disease progresses to dementia.

Dr. Steve Allder, a consultant neurologist who wasn’t involved in the study, told Newsweek: “This is an encouraging piece of research that adds another important piece to the Alzheimer’s puzzle.”

Brain Immune Cells May Hold the Answer

Alzheimer’s disease is often linked to the buildup of two proteins in the brain: amyloid plaques and tau tangles. But having these changes doesn’t always mean someone will develop memory loss or dementia.

To investigate why some people remain mentally sharp despite Alzheimer’s-related brain changes, researchers from Vlaams Instituut voor Biotechnologie, KU Leuven and Muna Therapeutics in Belgium, alongside the UK Dementia Research Institute, studied brain tissue from people with dementia, cognitively healthy older adults and centenarians.

They focused on microglia—the brain’s immune cells—which help protect and monitor the brain. The researchers found that these cells behave differently as Alzheimer’s develops.

They identified what appeared to be different stages of the disease. Early on, microglia switched into an inflammatory state linked to amyloid plaques—abnormal levels of this naturally occurring protein clump together to form plaques that disrupt cell function, according to the National Institute on Aging. Later, some microglia moved into a different immune state that appeared alongside tau buildup and brain cell damage.

The findings suggest this shift may be an important turning point that helps determine whether Alzheimer’s-related changes in the brain eventually lead to dementia.

Allder, who works at Re:Cognition Health, in Birmingham, England, told Newsweek: “For many years, research has concentrated on removing amyloid plaques, but this work suggests that maintaining a healthy immune response within the brain could be just as important.“If we can understand what allows these protective mechanisms to continue working, we may eventually be able to delay or even prevent symptoms, despite the presence of Alzheimer’s pathology.”

Not Everyone Resists Alzheimer’s the Same Way

The researchers also found that people who remained mentally sharp despite having Alzheimer’s pathology did not all follow the same pattern.

Some older adults who had amyloid plaques but no dementia showed the early microglial response but never moved into the later immune state linked to disease progression.

Meanwhile, cognitively healthy centenarians appeared to activate that later immune response, but it was largely not connected to tau buildup.

This suggests that resilience to Alzheimer’s may not simply come from avoiding the disease-related changes in the brain. It may also depend on how the brain responds and adapts to those changes.

“Understanding better how the brain resists the disease will provide new avenues towards therapies to prevent neurodegeneration and dementia,” said study corresponding author Professor Mark Fiers.

The findings could help guide future Alzheimer’s treatments. Rather than focusing only on removing amyloid plaques, scientists may also look at ways to influence microglia and help preserve the immune responses associated with resilience.

“These findings open new opportunities to target microglial states—especially pathways such as TREM2—and extend resilience rather than simply focusing on plaque removal.

“We are excited to continue this journey and understand the causal role of microglial transitions leading to the identification of novel therapeutic approaches to delay or prevent disease progression,” said Niels Plath, chief scientific officer of Muna Therapeutics, in a statement.

Reference

Vlaams Instituut voor Biotechnologie. (2026, July 26). A hidden Alzheimer’s tipping point may decide who gets dementia. ScienceDaily. Retrieved July 26, 2026 from www.sciencedaily.com/releases/2026/07/260726015257.htm

Contact Newsweek editors on this story: Charlotte Nisbet and Emma Lee-Sang

Related Articles

• Married Couple Stop Sleeping in Same Bed—Then They Notice a Change 
• Couple Uncover Bricked-Up Wall in Cellar—Then Find Cash Hidden for Decades
• Woman Drinks 10 Coffees a Day—Then Doctors Revealed the Damage to Her Heart

Start your unlimited Newsweek trial

Cognitive-motor network integration as a behavioral marker of cognitive reserve in post-stroke rehabilitation

 This did nothing to answer the real need! HOW EXACTLY DO YOU REBUILD COGNITIVE RESERVE post stroke so you can weather getting dementia/Alzheimers (per Bernadette the nun) and not have problems?

Cognitive-motor network integration as a behavioral marker of cognitive reserve in post-stroke rehabilitation

• 

  Katharina Kreiger 1,2*

• E

  Elisabeth Weiss 1

• 

  Felix Fluri 2,3

• 1. Faculty of Psychology, University of Innsbruck, Innsbruck, Austria

• 2. Kliniken Valens, Rheinburg Klinik, Walzenhausen, Switzerland

Abstract

Background:

Functional recovery after stroke varies substantially between individuals, even after standardized inpatient rehabilitation. Cognitive reserve is increasingly considered a key determinant of recovery potential, yet it is typically approximated using indirect proxy measures that may not capture the underlying functional mechanisms of recovery. Network-based approaches may provide a more mechanistic operationalization of cognitive reserve.

Objective: 

This study investigated whether (a) traditional cognitive reserve proxies predict rehabilitation response, (b) responders differ from non-responders in respect to baseline cognitive performance structure, and (c) rehabilitation response is associated with greater cross-domain cognitive-motor network integration at admission.

Methods: 

In this retrospective cohort study, 100 patients (≥ 65 years) with ischemic stroke were included. Functional outcomes were assessed using a battery of motor tests at admission and discharge. A responder was defined as someone who improved in at least two functional domains. Cognitive performance was assessed using the CERAD battery. Cognitive reserve proxies included years of education and engagement in leisure activity domains. Group differences and predictors of responder status were examined using regression models controlling for stroke severity (NIHSS).

Results: 

Cognitive leisure activities emerged as the strongest predictor of responder status (OR = 4.84), whereas education and other leisure domains were not retained. Exploratory factor analysis revealed two baseline cognitive dimensions (Memory, Executive-Spatial), but responders did not show significantly higher baseline cognitive scores. Network analyses demonstrated a more integrated cognitive-motor architecture in responders, characterized by higher density and lower sparsity. Dexterity and delayed verbal recall showed the highest centrality in the responder network, alongside processing speed as a consistently contributing node across centrality indices.

Conclusion: 

Post-stroke cognitive reserve may be less dependent on a high cognitive performance or demographic proxies but may be due to a more integrative organization of cognitive-motor functioning. Our findings support a network-based conceptualization of cognitive reserve with direct implications for integrative rehabilitation strategies.

More at link.

A 'Youthful' Brain May Boost Alzheimer's Resilience

 Ask your competent? doctor EXACTLY how to have a youthful brain! No knowledge, fire them and have them fired for incompetence! Dead wood needs to be removed unceremoniously! They do know exactly why Bernadette the nun was able to function quite well even with Alzheimers? NO? They incompetently know nothing about Bernadette? That's a game changer showing complete incompetence!

A 'Youthful' Brain May Boost Alzheimer's Resilience

Key Takeaways

• Preserved global brain structure appeared to buffer cognitive decline in people with Alzheimer's pathology.
• Younger-appearing brains had weaker links between pathology and poorer outcomes in multiple cognitive domains.
• Other measures of brain reserve or cognitive reserve showed no clear protective cognitive effect.

Greater structural brain integrity appeared to buffer the cognitive consequences of Alzheimer's disease pathology, cross-sectional data suggested.

The study evaluated two markers of brain reserve -- brain-predicted age difference (brain-PAD) and a volumetric Alzheimer's disease signature -- in cognitively unimpaired older adults. Brain-PAD, a marker of overall structural brain health, uses MRI data to determine how much older or younger a brain appears relative to chronological age.

Two markers of cognitive reserve, socioeconomic status and years of education, also were assessed.

Brain-PAD moderated the association between Alzheimer's pathology and multiple cognitive domains, including episodic memory (β = -0.09), processing speed (β = -0.08), working memory (β = -0.10), and executive function/attentional control (β = -0.08), reported Kelsey Sewell, PhD, of Murdoch University School of Allied Health in Perth, Australia, and co-authors."Specifically, the negative association of greater Alzheimer's disease pathology with poorer cognition was weakest in individuals with younger-appearing brains," the researchers wrote in Neurology.

A latent socioeconomic status score also appeared to influence the relationship between Alzheimer's pathology and episodic memory (β = 0.08), but the association did not remain significant after correction for multiple comparisons, Sewell and colleagues noted. Neither years of education nor the volumetric Alzheimer's signature moderated pathology-cognition associations, they added.

"Our main finding was that maintaining good overall brain health may help reduce the impact of Alzheimer's‑related changes on cognitive function," Sewell said in a statement. "Things like exercise, maintaining a healthy diet, sleeping well, and finding new cognitive challenges can help to maintain a healthy brain."

About 20% to 30% of adults ages 65 to 75 show evidence of Alzheimer's pathology despite having no measurable cognitive impairment, Sewell and co-authors said. "This phenomenon is often attributed to resilience, a general term describing multiple reserve-related processes that enable the brain to maintain higher levels of cognitive performance and function with aging or disease," they wrote."Within this framework, two key concepts are 'cognitive reserve' defined as a property of the brain that allows for cognitive performance better than expected given the degree of brain changes and pathology, and 'brain reserve' defined as the neurobiological capacity of the brain at a given point in time," they stated.

The findings of this study support "the idea that preserved global brain structure reduces vulnerability to cognitive decline in the face of emerging pathology," noted Maria Carrigan, MSc, and Colin Groot, MSc, both of Amsterdam University Medical Center in the Netherlands, in an accompanying editorial.

"For clinicians, the key message is that preserved global brain health seems to matter even before symptoms emerge," Carrigan and Groot wrote.

"The study also raises important questions for future research," the editorialists added. "What biological processes underlie a younger-appearing brain? To what extent is brain-PAD modifiable through interventions targeting physical activity, vascular risk factors, or other lifestyle exposures? In addition, how does brain-PAD interact longitudinally with amyloid and tau accumulation to influence cognitive trajectories?"

Sewell and colleagues examined whether cognitive and brain reserve modified the relationship between Alzheimer's pathology and cognition in 621 cognitively unimpaired, physically inactive participants in the IGNITE exercise trial in the U.S.

Mean age was 70 years and 71% were women. The mean brain-PAD of the cohort was -4.05, indicating that participants' brains appeared younger than their chronological age, on average.

Alzheimer's pathology was assessed using plasma phosphorylated tau (p-tau)-217. A subgroup of 355 participants also underwent tau PET imaging. Brain age was estimated from T1-weighted images.

The researchers noted several limitations. The study was cross-sectional and could not determine causality: while accelerated brain aging might worsen the cognitive effects of Alzheimer's pathology, it's also possible that people with more advanced brain ages are more vulnerable to accumulating pathology.

Emerging evidence suggests that p-tau217 may not be entirely specific to Alzheimer's pathology, they acknowledged. Findings from participants who had tau PET imaging supported the associations seen in the study.

Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Connect:

Disclosures

Sewell had no disclosures. One co-author disclosed being an inventor on a University of Pittsburgh patent regarding the IPMS assay for Aβ peptides and serving as a consultant for Quanterix.

Carrigan and Groot had no relevant disclosures.

Primary Source

Neurology

Source Reference: Sewell KR, et al "Cognitive and brain reserve as modifiers of early Alzheimer disease-related cognitive vulnerability" Neurology 2026; DOI: 10.1212/WNL.0000000000214833.

Secondary Source

Neurology

Source Reference: Carrigan M, Groot C "Can a 'youthful' brain moderate vulnerability to Alzheimer disease?" Neurology 2026; DOI: 10.1212/WNL.0000000000214927.

Restoring Cellular Energy May Help Reverse Alzheimer’s Damage, Research Shows by mindbodygreen

 

I'm doing this, haven't seen any negatives and won't be waiting years for true results to come in. Don't follow me, I'm not medically trained, I just reads lots of abstracts.

• NAD (6 posts to May 2014)
• NAD+ precursor (3 posts to February 2018)

Your doctor and hospitals' responsibility here is GETTING HUMAN TESTING GOING! Can't do that? 

COMPLETE INCOMPETENCY! No excuses! Fire them all starting with the board of directors!

Restoring Cellular Energy May Help Reverse Alzheimer’s Damage, Research Shows

Can Alzheimer’s be reversed? 

It’s a question scientists (and families) have been grappling with for years—and one that, until recently, has been met with cautious skepticism rather than clear answers. But new research published in Cell Reports Medicine¹ just discovered a promising perspective. 

Using advanced Alzheimer’s mouse models alongside analyses of human brain tissue, scientists found evidence that restoring a single cellular molecule may do more than slow the disease. Under certain conditions, it appeared to reverse key features of Alzheimer’s, including cognitive decline.

The molecule is NAD⁺ (nicotinamide adenine dinucleotide), a compound central to cellular energy, DNA repair, and brain resilience. And according to this research, disruptions in NAD⁺ balance may be a defining feature of Alzheimer’s severity, one that could be modifiable under the right conditions.

Image by Javier Díez / Stocksy

May 13, 2026

Can Alzheimer’s be reversed? 

It’s a question scientists (and families) have been grappling with for years—and one that, until recently, has been met with cautious skepticism rather than clear answers. But new research published in Cell Reports Medicine1 just discovered a promising perspective. 

Using advanced Alzheimer’s mouse models alongside analyses of human brain tissue, scientists found evidence that restoring a single cellular molecule may do more than slow the disease. Under certain conditions, it appeared to reverse key features of Alzheimer’s, including cognitive decline.

The molecule is NAD⁺ (nicotinamide adenine dinucleotide), a compound central to cellular energy, DNA repair, and brain resilience. And according to this research, disruptions in NAD⁺ balance may be a defining feature of Alzheimer’s severity, one that could be modifiable under the right conditions.

mindbodygreen Functional Nutrition Training

Learn how to use food as medicine with a cutting-edge nutrition deep dive taught by the world's foremost health & wellness experts. Learn more about mindbodygreen's Functional Nutrition Training.

It’s still early science. But the implications are hard to ignore.

Why NAD⁺ matters for brain health

NAD⁺ plays a quiet but essential role in keeping brain cells alive and functional. It helps neurons generate energy, repair DNA damage², manage oxidative stress, maintain the blood-brain barrier, and clear damaged proteins before they accumulate.

As we age, NAD⁺ levels naturally decline. But this study suggests Alzheimer’s disease involves a far more dramatic breakdown of NAD⁺ homeostasis, essentially tipping the brain into an energy and repair crisis it can’t recover from on its own.

That breakdown appears to separate people who develop cognitive symptoms from those who don’t. Interestingly, some individuals die with significant Alzheimer’s pathology in their brains yet remain cognitively intact during life. When researchers examined these brains, they found signs of preserved NAD⁺ balance, hinting at a built-in resilience mechanism.

Does this help to explain why Bernadette the nun was able to function quite well even with Alzheimers?

How scientists tested Alzheimer’s reversibility

To explore whether restoring NAD⁺ balance could actually change disease trajectory, researchers used two well-established mouse models of advanced Alzheimer’s, one driven by amyloid buildup and another by tau pathology.

Rather than targeting amyloid directly, the team administered a compound called P7C3-A20, designed to restore physiological NAD⁺ levels without pushing them above normal ranges. This distinction matters, since excessively high NAD⁺ levels may carry risks of their own.

So…what did they find? 

In mice with already advanced Alzheimer’s-like disease, restoring NAD⁺ balance reversed hallmark features of the condition: tau phosphorylation, brain inflammation, oxidative stress, blood-brain barrier damage, and impaired neurogenesis. Most notably, the mice regained cognitive function, performing on memory tasks as well as healthy controls.

To see whether these findings were relevant to humans, researchers analyzed brain tissue from people who had died with Alzheimer’s. The more severe the disease, the greater the disruption in NAD⁺ metabolism, mirroring what they observed in mice.

What the findings suggest about Alzheimer’s progression

This research challenges the long-held assumption that cognitive decline in Alzheimer’s is driven primarily by irreversible neuron loss. Instead, it suggests that much of the early and mid-stage decline may stem from dysfunctional cellular processes, ones that leave neurons impaired but not yet dead.

When NAD⁺ homeostasis was restored, neurons regained function. Protein buildup decreased. Synaptic communication improved. Even markers used clinically to track Alzheimer’s severity dropped.

In other words, the brain’s decline may be less about permanent destruction and more about failing resilience.

That shift in thinking opens the door to entirely new therapeutic strategies.

Prevention & brain longevity

It’s important to be clear that this was not a clinical trial in humans, and P7C3-A20 is not an approved Alzheimer’s treatment. But the study highlights NAD⁺ balance as a powerful upstream target, one that influences many of the processes known to drive neurodegeneration.

For everyday brain health, it reinforces a growing theme. Protecting cellular energy and repair systems matters. Sleep, regular movement, metabolic health, stress management, and nutrient sufficiency all influence NAD⁺ pathways. While lifestyle alone won’t reverse Alzheimer’s, these factors may help preserve brain resilience long before the disease takes hold.

RELATED READ: Interested In Creatine For Brain Health? Make Sure To Pair It With This

The takeaway

Alzheimer’s disease has long been treated as an unstoppable process. This study offers a more hopeful (and more nuanced) view.

By restoring NAD⁺ homeostasis, researchers were able to reverse cognitive and biological features of advanced Alzheimer’s in animal models and identify parallel disruptions in human brains. 

It’s early, but the message is meaningful: Alzheimer’s progression may leave more room for intervention than we once believed.

Could a fingerprick at home flag your Alzheimer's risk? New study says yes

Does your competent? doctor have the EXACT PREVENTION PROTOCOLS  if this is found? Oh NO, they haven't put Bernadette the nuns' method into practice have they? Why Bernadette the nun was able to function quite well even with Alzheimers?

Do you prefer your doctor, hospital and board of director's incompetence NOT KNOWING? OR NOT DOING? Your choice; let them be incompetent or demand action!

Could a fingerprick at home flag your Alzheimer's risk? New study says yes

A simple fingerprick taken at the kitchen table and dropped in the post could soon help identify who is most at risk of Alzheimer's disease, long before symptoms tighten their grip. In a new  study, researchers show that self-collected capillary blood, paired with online cognitive tests, matches the accuracy of traditional clinic-based sampling, opening the door to earlier, more equitable, and far more accessible dementia risk screening.

Study: Alzheimer’s Disease blood biomarkers measured through remote capillary sampling correlate with cognition in older adults. Image Credit: nito / Shutterstock

In a recent study published in Nature Communications, researchers found that self-administered fingerprick blood tests measuring plasma phosphorylated tau at amino acid 217 (p-tau217), along with glial fibrillary acidic protein (GFAP), closely aligned with conventional venous blood biomarkers. The markers were also associated with cognitive and functional performance across the Alzheimer's disease (AD) continuum. The findings suggest that combining these capillary blood tests with computerized cognitive assessments could support remote, at-home triage of individuals at risk of AD-related impairment, though the authors emphasize the approach is intended for risk stratification, not diagnosis. High patient acceptability further underscores its potential to improve early detection.

AD places a major burden on individuals, families, and healthcare systems, progressively impairing memory, independence, and quality of life. Despite advances in biomarker research, many people with early cognitive impairment remain outside specialist care, delaying diagnosis and intervention. Blood biomarkers such as p-tau217 and GFAP have emerged as promising tools for detecting AD-related pathology. However, current venous blood testing still requires clinic visits, limiting accessibility and scalability. This underscores the need for scalable approaches that extend risk assessment beyond specialist settings and support earlier identification of high-risk individuals.

Capillary Sampling Study Design

Building on earlier work validating capillary sampling against venous blood and cerebrospinal fluid markers, researchers evaluated whether a self-administered capillary blood test could support scalable triage for AD when collected remotely and returned by post.

The researchers included 174 participants spanning cognitively healthy adults, individuals with mild cognitive impairment (MCI), and patients with mild to moderate AD dementia, though only 28 participants had dementia, which limits the robustness of group-discrimination analyses. They recruited individuals with dementia through primary and secondary care sites across the South-West United Kingdom using established diagnostic criteria. Cognitively healthy individuals were drawn from the Platform for Research Online To investigate gEnetics and CogniTion and ageing (PROTECT-UK) study. The cohort was predominantly white and UK-based, so generalizability to other ethnic, socioeconomic, and healthcare contexts remains unconfirmed.

Using written and video instructions, participants collected fingertip capillary blood samples at home and returned them by post. Additionally, 40 of them provided venous blood samples for comparison of sampling methods. Researchers then quantified GFAP and p-tau217 using ultrasensitive immunoassay platforms (highly sensitive lab tests capable of detecting low levels of these proteins in blood).

Participants also completed a comprehensive assessment of cognition, function, and health status. Using a computerized testing platform developed within the PROTECT study, the team evaluated executive function, attention, and memory through tasks assessing recall, associative memory, reaction speed, verbal reasoning, and working memory.

Further, the team measured functional ability using the Lawton Instrumental Activities of Daily Living (IADL) scale. They then used the informant questionnaire on cognitive decline in older adults (IQCODE) to assess cognitive decline. Participants also provided information on vascular health conditions through structured medical history questionnaires. In addition, they completed an online Likert-scale survey evaluating usability, user experience, and readiness to adopt the at-home sampling method, with caregiver support provided where necessary. The researchers assessed correlations between blood-based biomarkers and cognitive outcomes. Logistic regression models explored associations between biomarker status and vascular risk factors, adjusting for age and sex.

p-tau217 and GFAP Cognitive Findings

The study included 146 cognitively normal individuals and 28 with dementia. Participants had a mean age of 66 years, and 54% were female. Both capillary biomarkers showed significant associations with cognitive performance. Elevated p-tau217 levels were linked to poorer memory, attentional processing, and higher-order cognitive abilities. GFAP was similarly associated with deficits in working memory and executive processing.

Functional findings showed a comparable trend. Elevated p-tau217 levels were associated with both daily functioning and cognitive decline scores, whereas GFAP was linked only to functional ability measures. Both biomarkers also significantly discriminated between participants with and without dementia in receiver operating characteristic (ROC) curve analyses (a standard method for evaluating diagnostic test performance), supporting their role in triage rather than as standalone diagnostic tests, particularly given the modest sensitivity (35%) of the chosen thresholds.

Using predefined thresholds prioritising 85% specificity (favoring few false positives at the cost of missing some true cases), researchers identified distinct at-risk groups. Participants exceeding the biomarker threshold values showed significantly poorer cognitive and functional performance across most domains. A dual-threshold approach combining p-tau217 with episodic memory performance, flagging individuals who scored abnormally on both tests, further refined stratification, identifying a high-risk group comprising 9% of participants with marked impairment and a low-risk group with consistently better performance across measures.

Notably, researchers found minimal overlap between the two biomarkers, with only 6% of participants testing positive for both. GFAP positivity was strongly linked to heart disease (odds ratio 4.14, 95% CI 1.31–13.10), indicating GFAP-positive individuals had roughly four times higher odds of reporting a cardiac history, pointing to a potential association with vascular-related cognitive impairment, while p-tau217 showed no such relationship.

The team also found strong agreement between capillary and venous biomarker measurements (r = 0.71–0.79 across diagnostic subgroups, including cognitively healthy and dementia participants), supporting the validity of the home-based method. Eighty percent of participants completed the test independently, and nearly all (96%) indicated they would be willing to use it as part of routine healthcare, though stated willingness does not necessarily translate to successful independent use, as the 20% requiring assistance demonstrates.

At-Home Alzheimer’s Triage Implications

The findings support capillary p-tau217, particularly when combined with computerized cognitive testing, as a scalable, remote triage tool for identifying individuals at the highest risk of AD-related impairment, while GFAP may provide additional insight into vascular-related cognitive decline.

The study showed strong agreement between capillary and venous biomarkers and validated the use of self-collected home samples, reinforcing the feasibility of this approach outside clinical settings. High patient acceptability further supports real-world implementation. Rather than diagnosing disease, this approach could enable earlier risk stratification and improve clinical pathways. It may also streamline clinical trial recruitment, where screen failure rates in preclinical AD trials currently reach as high as 90%.

Future studies should validate findings in independent and more diverse cohorts, benchmark against amyloid and tau PET imaging, assess longitudinal predictive value, and refine self-testing instructions (since 20% of participants required assistance) to integrate this strategy into primary care and research settings.

Readers should also note that commercial immunoassay platforms were used in this work, and funding and competing-interest disclosures should be reviewed in the original publication.

Journal reference:

• Corbett, A., Sander-Long, M., Ashton, N.J. et al. (2026). Alzheimer's Disease blood biomarkers measured through remote capillary sampling correlate with cognition in older adults. Nature Communications, 17, 3699. DOI: 10.1038/s41467-026-71448-2, https://www.nature.com/articles/s41467-026-71448-2